Slide 1: ChromaDex Earnings Conference Call First Quarter 2022
ChromaDex Earnings Conference Call First Quarter 2022 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934
Slide 3: Q1 2022 & Recent Highlights
3 Q1 2022 & Recent Highlights • Total company and Tru Niagen® net sales up 18% and 20% YoY, respectively, with 13% growth in E-Commerce. • Delivered gross margins of 61.0% a (190) basis point decline YoY primarily driven by business mix. • Selling and marketing expense reflected investments in brand
Slide 4: Management Team
Management Team Rob Fried Chief Executive Officer E-Commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Frank Jaksch Executive Chairman Co-founded ChromaDex in 2000 Kevin Farr Chief Financial Officer Former CFO, Mattel PriceWate
Slide 5: The Science
The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) The Science 5
Slide 6: Science Continues to Expand
6 Science Continues to Expand ◦ One new human trial on nicotinamide riboside registered since prior update:¹ ◦ Haukeland University Hospital (April 2022) - NRSAFE ◦ This is a continuation of the work by Dr. Tzoulis from the NADPARK and NO-PARK trials ◦ NADPARK showed that NR supplementation signific
Slide 7: Scientific Advisory Board
Scientific Advisory Board Charles Brenner, Ph.D. Alfred E Mann Family Foundation Chair, Department of Diabetes & Cancer Metabolism City of Hope World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.D. Chairman Professor of Structural Biology Stanford University Nobel Prize Winner, Chemistr
Slide 8: Basic Physiological Functions are NAD+ Dependent
Basic Physiological Functions are NAD+ Dependent INTRINSIC CAPACITY DOMAIN Based on World Health Organization’s definition VITALITY Energy metabolism Hormonal function Cardio-respiratory function Number of clinical trials (active)* 14 Number of clinical trials (complete)* 8 % of all registered Niage
Slide 9: Financial Highlights
The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) 9 Financial Highlights
Slide 10: Q1 2022 Net Sales Mix
10 Q1 2022 Net Sales Mix e-Commerce 65% Watson's & Other B2B 19% Niagen® Ingredient 8%Analytical Reference Standards & Services 6% Other Ingredients 1% Q1 2021 $14.7 MM e-Commerce 63% Watson's & Other B2B 24% Niagen® Ingredient 6% Analytical Reference Standards & Services 5% Other Ingredients 2% $17
Slide 11: Q1 2022 Net Sales
11 Q1 2022 Net Sales Q1 2022 Net Sales ($ in millions) 10.9 4.1 1.1 0.9 0.3 e-Commerce Watson's & Other B2B Niagen® Ingredient Analytical Reference Standards & Services Other Ingredients $14.9 Growth Rates YoY % (vs Q1 2021) QoQ % (vs Q4 2021) +13% (2)% +43% +36% (6)% (56)% (4)% +4% +164% +19% +18%
Slide 12: 2020 – 2022 YTD Net Sales Summary
12 2020 – 2022 YTD Net Sales Summary (in millions) 2020 2021 2022 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Ecommerce 8.2 8.1 8.7 9.5 34.5 9.6 10.6 10.5 11.1 41.8 10.9 Watsons 1.8 1.3 2.5 2.1 7.6 1.6 2.9 2.6 2.2 9.3 2.5 Other B2B 1.1 2.3 0.8 0.8 5.0 1.3 1.8 1.6 0.8 5.6 1.5 Total TRU NIAGEN 11.1 1
Slide 13: Q1 2022 vs Q4 2021 Key P&L Metrics
13 Q1 2022 vs Q4 2021 Key P&L Metrics (in thousands) Q1 2022 Q4 2021 Notes Net Sales 17,259 17,759 Tru Niagen® business up 6% driven by increased Watsons and Other B2B sales, offset by lower E-Commerce (down (2)%) due to absence of key promotional events in China Gross Profit % of Net Sales 10,532 6
Slide 14: Q1 2022 vs Q1 2021 Key P&L Metrics
14 Q1 2022 vs Q1 2021 Key P&L Metrics (in thousands) Q1 2022 Q1 2021 Notes Net Sales 17,259 14,683 Tru Niagen® business up 20% driven by global e-Commerce growth and higher Watson's sales, following last year's supply chain disruption Gross Profit % of Net Sales 10,532 61.0% 9,234 62.9% Down (190)bp
Slide 15: Adjusted EBITDA Summary
15 Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 March 31, 2022 Net los
Slide 16: Q1 2022 Operating Loss vs Q1 2021
16 Q1 2022 Operating Loss vs Q1 2021 (7.4) 1.6 2.7 (0.3) (0.3) (0.6) (0.6) (0.8) (2.0) (7.7) Q1 2021 Operating Loss Volume Legal Gross Margin Decline Research and Development Equity Comp (G+A) Other G+A Severance and Restructuring Sales & Marketing Q1 2022 Operating Loss (9.0) (8.0) (7.0) (6.0) (5.0
Slide 17: Quarterly Balance Sheet Highlights
17 Quarterly Balance Sheet Highlights (in thousands) 12/31/19 12/31/20 3/31/21 6/30/21 9/30/21 12/31/21 3/31/22 Key Drivers (YoY for 2022 YTD) Cash $ 18,812 $16,697 $44,691 $38,778 $33,102 $28,219 $20,993 Cash used in operations to grow the business and protect our IP Inventory 11,535 11,683 12,762
Slide 18: Quarterly Cash Flow Highlights
18 Quarterly Cash Flow Highlights (in thousands) FY 2019 FY 2020 3/31/21 6/30/21 9/30/21 12/31/21 FY 2021 3/31/22 Net Loss $ (32,147)(4) $ (19,925) $ (7,381) $(5,566) $(8,856) $(5,325) $(27,128) $(7,740) Working Capital 2,026(1) 383 258 (4,390) 942 (1,670) (4,915) (1,923) Cash From / (Used for) Oper
Slide 19: 2022 Financial Outlook
19 2022 Financial Outlook (in thousands) 2020 Actual 2021 Actual 2022 Full Year (“FY”) Outlook Key Drivers (Current FY Outlook) Net Sales $59,257 $67,449 '+15-20%YoY (No change) • Tailwinds:E-Commerce, new partnerships • Headwinds: COVID-19 impact on Watsons and New Zealand and Australia Distributor
Slide 20: Q1 2022 Financial Highlights - Recap
20 Q1 2022 Financial Highlights - Recap • Total net sales of $17.3 million in Q1 2022 (+18% YoY, (3)% versus Q4 2021) • Continued progress building the Tru Niagen® brand ◦ Tru Niagen® net sales of $14.9 million in Q1 2022 (+20% YoY, +6% vs Q4 2021) • Continuously strong gross margin ((20)bps vs Q4 2
Slide 21: Contact Info
The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) Contact Info Brianna Gerber Vice President of Finance and Investor Relations T: +1.9